Overview

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Status:
Completed
Trial end date:
2020-11-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
Phase:
Phase 2
Details
Lead Sponsor:
Revance Therapeutics, Inc.
Treatments:
abobotulinumtoxinA
Botulinum Toxins, Type A